Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial - Eggermont, AM M; Kicinski, M; Blank, C U (JAMA Oncol, 2020)
et al.